EUVIMEDOtkrijte EUVIMED
CrossrefInformacijska kartica

CEACAM1 participation in breast cancer progression

Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth

Molecular Oncology · 2026-11 · 20 (11) · 2805-2819

DOI: 10.1002/1878-0261.70306 ↗
SažetakBibliografski podaci

Sažetak

Carcinoembryonic antigen‐related cell adhesion molecule 1 (CEACAM1) is widely expressed in human cells and undergoes marked alterations during tumorigenesis. However, its functional significance in invasive breast cancer (BC) remains insufficiently understood. In this study, CEACAM1 expression patterns in invasive BC tissues were analyzed and correlated with the proliferative index (PI) of the tumor cells. To assess isoform‐specific functional effects and identify CEACAM1‐responsive genes involved in key proliferation‐associated pathways, MCF‐7 cells were transfected with either CEACAM1 short cytoplasmic domain isoform (CEACAM1‐4S) or CEACAM1 long cytoplasmic domain isoform (CEACAM1‐4L). BC tissues exhibited substantial heterogeneity in CEACAM1 expression, which correlated with the PI of the tumor cells. Functional in vitro studies demonstrated that the CEACAM1‐4L isoform exclusively suppresses cell proliferation. Transcriptome and protein‐level analyses revealed that CEACAM1‐4L regulates the expression of key mediators involved in cell cycle control, apoptosis, extracellular matrix organization, and growth factor‐dependent signaling pathways. These findings highlight the biological significance of CEACAM1‐4L isoform in BC, its potential diagnostic relevance for patient stratification, as well as its possible consideration in future therapeutic approaches.

Znanje koje odgovara vašem radu.

Od besplatnog početka i osobnog pretraživanja literature do potpunog paketa Research Suite.

Prikaži tarife →

Jesu li uključeni svi cjeloviti tekstovi izdavača?

Ne. Bibliografski zapisi, sažeci i cjeloviti tekstovi različiti su sadržaji. Hoće li cjeloviti tekst biti dostupan ovisi o izvoru, Open Accessu i vašim postojećim licencama. Tarifa EUVIMED ne zamjenjuje dodatna izdavačka prava.

Prikaži tarife →